Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Phase 1

Active, not recruiting

Conditions: COVID-19 Immunization
Influenza Immunization

Interventions: Biological: IIV-HD + rC19 (dose 3)
Biological: IIV-HD + rC19 (dose 4)
Biological: IIV-HD
Biological: rC19 (dose 1)
Biological: IIV-HD + rC19 (dose 1)
Biological: IIV-HD + rC19 (dose 2)
Other: Placebo (0.9% NaCl)

First Posted Date: 2024-11-19

Last Posted Date: 2025-04-01

Lead Sponsor: Sanofi

Target Recruit Count: 980

Registration Number: NCT06695117

Locations: 🇺🇸
Synexus New York Site Number : 8400007, New York, New York, United States
🇺🇸
Simon Williamson Clinic - Birmingham- Site Number : 8400003, Birmingham, Alabama, United States
🇺🇸
Synexus Clinical Research- Site Number : 8400004, Chicago, Illinois, United States

and more 9 locations

A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

Recruiting

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Dupilumab

First Posted Date: 2024-11-19

Last Posted Date: 2025-05-09

Lead Sponsor: Sanofi

Target Recruit Count: 150

Registration Number: NCT06695897

Locations: 🇩🇪
Investigational Site Number: 0000001, Dachau, Bayern, Germany

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Phase 1

Active, not recruiting

Conditions: COVID-19 Immunization
Influenza Immunization

Interventions: Biological: RIV + rC19 (dose 4)
Biological: RIV (recombinant influenza vaccine)
Biological: rC19 (dose 1)
Biological: RIV + rC19 (dose 1)
Biological: RIV + rC19 (dose 2)
Biological: RIV + rC19 (dose 3)
Other: Placebo (0.9% NaCl)

First Posted Date: 2024-11-19

Last Posted Date: 2025-05-28

Lead Sponsor: Sanofi

Target Recruit Count: 980

Registration Number: NCT06695130

Locations: 🇺🇸
Optimal Research - Illinois- Site Number : 8400008, Peoria, Illinois, United States
🇺🇸
Synexus Clinical Research US - Minneapolis- Site Number : 8400011, Richfield, Minnesota, United States
🇺🇸
Synexus-Las Vegas- Site Number : 8400005, Las Vegas, Nevada, United States

and more 9 locations

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

Phase 2

Recruiting

Conditions: Chronic Rhinosinusitis Without Nasal Polyps

Interventions: Drug: Itepekimab (SAR440340)
Drug: Mometasone furoate nasal spray (MFNS)
Drug: Placebo

First Posted Date: 2024-11-15

Last Posted Date: 2025-05-20

Lead Sponsor: Sanofi

Target Recruit Count: 60

Registration Number: NCT06691113

Locations: 🇨🇱
Investigational Site Number : 1520002, Concepción, Biobío, Chile
🇺🇸
Alabama Allergy & Asthma Center - Birmingham - Brookwood Boulevard- Site Number : 8400006, Birmingham, Alabama, United States
🇺🇸
Western States Clinical Research- Site Number : 8400009, Wheat Ridge, Colorado, United States

and more 50 locations

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

Phase 3

Recruiting

Conditions: Lichen Simplex Chronicus

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2024-11-14

Last Posted Date: 2025-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 136

Registration Number: NCT06687967

Locations: 🇬🇷
Investigational Site Number : 3000003, Thessaloniki, Greece
🇭🇺
Investigational Site Number : 3480001, Debrecen, Hungary
🇮🇹
Investigational Site Number : 3800001, Rome, Roma, Italy

and more 46 locations

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

Phase 3

Recruiting

Conditions: Lichen Simplex Chronicus

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2024-11-14

Last Posted Date: 2025-05-20

Lead Sponsor: Sanofi

Target Recruit Count: 136

Registration Number: NCT06687980

Locations: 🇦🇷
Investigational Site Number : 0320203, Córdoba, Argentina
🇨🇳
Investigational Site Number : 1560202, Guangzhou, China
🇩🇪
Investigational Site Number : 2760201, Berlin, Germany

and more 44 locations

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Phase 1

Recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Amlitelimab
Drug: Midazolam
Drug: Caffeine
Drug: Metoprolol
Drug: Omeprazole
Drug: Warfarin

First Posted Date: 2024-11-13

Last Posted Date: 2024-12-27

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT06686628

Locations: 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

Recruiting

Conditions: Hemophilia A

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2024-11-12

Last Posted Date: 2025-01-30

Lead Sponsor: Sanofi

Target Recruit Count: 120

Registration Number: NCT06684314

Locations: 🇨🇳
Investigational Site Number : 1580001, Taipei City, Taiwan
🇨🇳
Investigational Site Number : 1580002, Taipei City, Taiwan
🇨🇳
Investigational Site Number : 1580004, Taoyuan City, Taiwan

and more 5 locations

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Lunsekimig
Drug: Short-Acting Beta Agonists (SABA)
Drug: Placebo
Drug: Fluticasone/salmeterol
Drug: Budesonide/formoterol

First Posted Date: 2024-11-06

Last Posted Date: 2025-05-21

Lead Sponsor: Sanofi

Target Recruit Count: 1000

Registration Number: NCT06676319

Locations: 🇺🇸
Chandler Clinical Research Trials- Site Number : 8400075, Chandler, Arizona, United States
🇺🇸
Epic Medical Research - Surprise- Site Number : 8400052, Surprise, Arizona, United States
🇺🇸
Tucson Clinical Research Institute - Site number: 8400085, Tucson, Arizona, United States

and more 157 locations

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Phase 4

Recruiting

Conditions: Type 2 Diabetes (T2D)

Interventions: Drug: iGlarLixi (insulin glargine/lixisenatide)
Drug: Gla-100 (insulin glargine)

First Posted Date: 2024-11-04

Last Posted Date: 2024-12-12

Lead Sponsor: Sanofi

Target Recruit Count: 678

Registration Number: NCT06671587

Locations: 🇨🇳
Investigational Site Number: 1560001, Beijing, China

Home Terms & Conditions Privacy Policy